6868 Results (Page 6 of 275)
Pharmaceuticals Markets Research Reports
Germany Atherosclerosis Therapeutics Market Analysis
Germany Atherosclerosis therapeutics market was valued at $102 Mn in 2022 and is estimated to reach $139 Mn in 2030, exhibiting a CAGR of 3.9% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the rising incidence of cardiovascular diseases, which are exacerbated by sedentary lifestyles, poor eating habits, and an aging population worldwide. Well-known pharmaceutical companies that presently hold a significant share of the market include Sanofi, Novartis, Pfizer, Bayer, AstraZeneca, Merck Sharp & Dohme, AbbVie, Roche, Johnson & Johnson, and Bristol-Myers Squibb
France Atherosclerosis Therapeutics Market Report 2022 to 2030
France Atherosclerosis Therapeutics Market was valued at $77 Mn in 2022 and is estimated to reach $111 Mn in 2030, exhibiting a CAGR of 4.7% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the rising incidence of cardiovascular diseases, which are exacerbated by sedentary lifestyles, poor eating habits, and an aging population worldwide. The market is currently dominated by leading pharmaceutical companies, including Sanofi, Novartis, Pfizer, Bayer, AstraZeneca, Merck Sharp & Dohme, AbbVie, Roche, Johnson & Johnson and Bristol-Myers Squibb.
Egypt Atherosclerosis Therapeutics Market Analysis
Egypt Atherosclerosis Therapeutics Market was valued at $8 Mn in 2022 and is estimated to reach $14 Mn in 2030, exhibiting a CAGR of 7.2% during the forecast period. The rising prevalence of cardiovascular diseases, exacerbated by unhealthy dietary patterns, sedentary lifestyles, and a growing aging population worldwide, is anticipated to increase the need for atherosclerosis therapeutics. Leading pharmaceutical companies currently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Abbott, Eli Lilly, GlaxoSmithKline, Teva Pharmaceutical, and Roche.
China Atherosclerosis Therapeutics Market Analysis
China Atherosclerosis Therapeutics Market was valued at $225 Mn in 2022 and is estimated to reach $393 Mn in 2030, exhibiting a CAGR of 7.2% during the forecast period. The market for atherosclerosis therapeutics is expected to rise as a result of the increasing prevalence of cardiovascular illnesses that have been exacerbated by unhealthy eating habits, sedentary lifestyles, and an aging population worldwide. The top leading pharmaceutical companies presently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Merck & Co., China Resources Pharmaceutical Group, Huahai Pharmaceutical Group, Jiangsu Hengrui Medicine Co., Qilu Pharmaceutical Co. and Yisheng Pharmaceutical Co.
Canada Atherosclerosis Therapeutics Market Analysis
Canada Atherosclerosis Therapeutics Market was valued at $224 Mn in 2022 and is estimated to reach $349 Mn in 2030, exhibiting a CAGR of 5.7% during the forecast period. The increasing prevalence of cardiovascular diseases, driven by the global aging population and rising occurrences of sedentary behaviour and unhealthy diets, is expected to fuel the demand for atherosclerosis therapeutics. The leading pharmaceutical companies currently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Johnson & Johnson, Eli Lilly, AbbVie, Roche and Teva Pharmaceutical Industries
Brazil Atherosclerosis Therapeutics Market Analysis
Brazil Atherosclerosis Therapeutics Market was valued at $70 Mn in 2022 and is estimated to reach $118 Mn in 2030, exhibiting a CAGR of 6.7% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the growing incidence of cardiovascular diseases, which are being exacerbated by sedentary lifestyles, poor eating habits, and an aging population worldwide. The leading pharmaceutical companies presently operating in the market are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Abbott, Johnson & Johnson, Teva Pharmaceutical, Roche, and Merck & Co.
Vietnam Asthma and COPD Therapeutics Market Analysis
The Vietnam Asthma and COPD Therapeutics Market was valued at US $167 Mn in 2022, and is predicted to grow at (CAGR) of 5.43% from 2023 to 2030, to US $255 Mn by 2030. The key drivers of this industry include the surge in the prevalence of COPD and asthma, supportive government initiatives, improved healthcare infrastructure, and others. The industry is primarily dominated by players such as Abbott, Mekophar, AstraZeneca, Traphaco, Novartis, Pharimexco, and GSK, among others.
US Asthma and COPD Therapeutics Market Analysis
The US Asthma and COPD Therapeutics Market was valued at US $14.03 Bn in 2022, and is predicted to grow at (CAGR) of 3.20% from 2023 to 2030, to US $18.05 Bn by 2030. The key drivers of this industry include the upward trend in the prevalence of COPD and asthma, advanced treatments, rising healthcare spending, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Teva US, GSK, Novartis Pfizer, and Boehringer Ingelheim, among others
UK Asthma and COPD Therapeutics Market Analysis
The UK Asthma and COPD Therapeutics Market was valued at US $0.868 Bn in 2022, and is predicted to grow at (CAGR) of 3.20% from 2023 to 2030, to US $1.117 Bn by 2030. The key drivers of this industry include the surge in the prevalence of COPD and asthma, demand for effective treatment, supportive government initiatives, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Teva, GSK, Novartis Pfizer, Boehringer Ingelheim, among others
UAE Asthma and COPD Therapeutics Market Analysis
The UAE Asthma and COPD Therapeutics Market was valued at US $167 Mn in 2022, and is predicted to grow at (CAGR) of 6.20% from 2023 to 2030, to US $270 Mn by 2030. The key drivers of this industry include the rising prevalence of COPD and asthma, supportive government initiatives, unmet demand, and others. The industry is primarily dominated by players such as, GlaxoSmithKline, Teva, Merck Novartis, AstraZeneca, Pfizer, and Boehringer Ingelheim, among others.
Spain Asthma and COPD Therapeutics Market Analysis
The Spain Asthma and COPD Therapeutics Market was valued at US $645 Mn in 2022, and is predicted to grow at (CAGR) of 4.20% from 2023 to 2030, to US $896 Mn by 2030. The key drivers of this industry include the rising burden of COPD and asthma, the impact of the COVID-19 pandemic, supportive regulations, and others. The industry is primarily dominated by players such as, GlaxoSmithKline, Teva, Pfizer, Novartis, AbbVie, AstraZeneca, and Boehringer Ingelheim, among others
South Africa Asthma and COPD Therapeutics Market Analysis
The South Africa Asthma and COPD Therapeutics Market was valued at US $217 Mn in 2022, and is predicted to grow at (CAGR) of 6.43% from 2023 to 2030, to US $357 Mn by 2030. The key drivers of this industry include the surge in the prevalence of COPD and asthma, supportive government initiatives, technological advancements, and others. The industry is primarily dominated by players such as Abbott, Aspen, AstraZeneca, Adcock, Novartis, Netcare, and GSK, among others.
Singapore Asthma and COPD Therapeutics Market Analysis
The Singapore Asthma and COPD Therapeutics Market was valued at US $40 Mn in 2022, and is predicted to grow at (CAGR) of 5.80% from 2023 to 2030, to US $63 Mn by 2030. The key drivers of this industry include the rise in the prevalence of COPD and asthma, growth in disposable income, increased awareness, and others. The industry is primarily dominated by players such as AstraZeneca, Teva, Novartis, GlaxoSmithKline, and Boehringer Ingelheim, among others.
Saudi Arabia Asthma and COPD Therapeutics Market Analysis
The Saudi Arabia Asthma and COPD Therapeutics Market was valued at US $568 Mn in 2022, and is predicted to grow at (CAGR) of 6.70% from 2023 to 2030, to US $954 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of COPD and Asthma, advanced treatments, rising healthcare spending, and others. The industry is primarily dominated by players such as, Novartis, Teva, GSK, Novartis, AstraZeneca, Pfizer, and Boehringer Ingelheim, among others
Philippines Asthma and COPD Therapeutics Market Analysis
The Philippines Asthma and COPD Therapeutics Market was valued at US $73 Mn in 2022, and is predicted to grow at (CAGR) of 5.70% from 2023 to 2030, to US $114 Mn by 2030. The key drivers of this industry include the rising prevalence of COPD and asthma, growing collaborations, improved healthcare infrastructure, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Teva, Sanofi, Pfizer, and GlaxoSmithKline, among others.
Mexico Asthma and COPD Therapeutics Market Analysis
The Mexico Asthma and COPD Therapeutics Market was valued at US $501 Mn in 2022, and is predicted to grow at (CAGR) of 5.45% from 2023 to 2030, to US $766 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of COPD and asthma, increasing demand, supportive policies, and others. The industry is primarily dominated by players such as, GlaxoSmithKline, Tetherex, Novartis, AstraZeneca, Verona, and Boehringer Ingelheim, among others
Malaysia Asthma and COPD Therapeutics Market Analysis
The Malaysia Asthma and COPD Therapeutics Market was valued at US $54 Mn in 2022, and is predicted to grow at (CAGR) of 5.40% from 2023 to 2030, to US $82 Mn by 2030. The key drivers of this industry include the rising prevalence of COPD and asthma, supportive government initiatives, improved healthcare infrastructure, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Chiesi, Sanofi, Pfizer, and GlaxoSmithKline, among others.
Kenya Asthma and COPD Therapeutics Market Analysis
The Kenya Asthma and COPD Therapeutics Market was valued at US $23 Mn in 2022, and is predicted to grow at (CAGR) of 6.30% from 2023 to 2030, to US $38 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of COPD and Asthma, supportive healthcare policies, increased awareness, and others. The industry is primarily dominated by players such as Abbott, Roche, AstraZeneca, Pfizer, Novartis, Cipla, and Boehringer-Ingelheim, among others.
Japan Asthma and COPD Therapeutics Market Analysis
The Japan Asthma and COPD Therapeutics Market was valued at US $2.076 Bn in 2022, and is predicted to grow at (CAGR) of 5.70% from 2023 to 2030, to US $3.235 Bn by 2030. The key drivers of this industry include the surge in the prevalence of COPD and Asthma, supportive government initiatives, advancements in technology, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Daiichi Sankyo, Chugai, Sumitomo, and Mochida, among others.
Indonesia Asthma and COPD Therapeutics Market Analysis
The Indonesia Asthma and COPD Therapeutics Market was valued at US $200 Mn in 2022, and is predicted to grow at (CAGR) of 5.20% from 2023 to 2030, to US $301 Mn by 2030. The key drivers of this industry include the increasing prevalence of COPD and Asthma, rising economic growth, advancements in therapeutics, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Pfizer, GSK, Novartis, Abbott, and Boehringer Ingelheim, among others.
Vietnam Anemia Therapeutics Market Analysis
The Vietnam Anemia Therapeutics Market is anticipated to experience a growth from $74 Mn in 2022 to $151 Mn by 2030, with a CAGR of 9.3% during the forecast period of 2022-2030. High anemia prevalence, changing demographic trends and urbanization, and increased government support in the betterment of healthcare access among the population are among some factors that boost Vietnam market. The Vietnam Anemia Therapeutics Market encompasses various players across different segments, including Novartis, Pfizer, Roche, Bayer, Johnson & Johnson, Sanofi, AstraZeneca, Traphaco, Mekophar, Sao Kim Pharmaceutical etc, among various others
Germany HIV Drugs Market Analysis
Germany HIV Drugs Market is at around $1.16 Bn in 2023 and is projected to reach $1.31 Bn in 2030, exhibiting a CAGR of 1.8% during the forecast period. Increasing HIV prevalence, increased awareness and testing, and technological breakthroughs drive market growth. The market is dominated by key players like Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd, Johnson & Johnson, and Bayer.
Singapore HIV Drugs Market Analysis
Singapore HIV Drugs Market is at around $38.04 Mn in 2023 and is projected to reach $50.74 Mn in 2030, exhibiting a CAGR of 4.2% during the forecast period. The market is being driven by developments in drug research, government initiatives, and the rising prevalence of HIV. The market is dominated by key players like Aslan Pharmaceuticals, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd., and Novartis.
Indonesia HIV Drugs Market Analysis
Indonesia HIV Drugs Market is at around $0.19 Bn in 2023 and is projected to reach $0.24 Bn in 2030, exhibiting a CAGR of 3.6% during the forecast period. The market is growing as a result of government initiatives, rising HIV prevalence, and the expansion of healthcare infrastructure. The market is dominated by key players like PT Dexa Medica, PT Sanbe Farma, ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd.
China HIV Drugs Market Analysis
China HIV Drugs Market is at around $2.55 Bn in 2023 and is projected to reach $3.61 Bn in 2030, exhibiting a CAGR of 5.1% during the forecast period. Increasing HIV/ AIDS prevalence, healthcare infrastructure improvement and new drug approvals and developments are all driving market expansion. The market is dominated by key players like Sinopharm, Jiangsu Hengrui Medicine, Shanghai Fosun Pharmaceuticals, ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, and AbbVie Inc.